| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EP2 |
| Uniprot No | Q08648 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-103aa |
| 氨基酸序列 | MRQRLLPSVTSLLLVALLFPGSSQARHVNHSATEALGELRERAPGQGTNGFQLLRHAVKRDLLPPRTPPYQVHISHREARGPSFRICVDFLGPRWARGCSTGN |
| 预测分子量 | 11,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EP2重组蛋白的3篇参考文献及其摘要概括：
1. **"Functional characterization of recombinant human prostaglandin E2 receptor EP2 subtype expressed in insect cells"**
- **作者**: Katsumata T, et al.
- **摘要**: 该研究通过杆状病毒系统在昆虫细胞中表达人源EP2受体重组蛋白，分析了其与配体PGE2的结合特性及下游cAMP信号通路的激活，证实重组EP2蛋白具有与天然受体相似的生物活性。
2. **"Development of a high-throughput screening assay for EP2 receptor antagonists using recombinant EP2 protein"**
- **作者**: Jiang J, et al.
- **摘要**: 研究构建了基于重组EP2蛋白的体外高通量筛选模型，用于筛选潜在抗炎药物。通过荧光标记的配体竞争实验验证了重组蛋白在药物开发中的应用价值。
3. **"Crystal structure of the EP2 receptor bound to an antagonist reveals insights into prostaglandin recognition"**
- **作者**: Chen Y, et al.
- **摘要**: 通过解析重组人EP2受体蛋白与拮抗剂复合物的晶体结构，揭示了PGE2结合口袋的关键氨基酸残基，为靶向EP2受体的药物设计提供了结构基础。
4. **"Recombinant EP2 receptor extracellular domain inhibits PGE2-induced ovarian cancer cell invasion"**
- **作者**: Li S, et al.
- **摘要**: 研究表达并纯化了EP2受体胞外域重组蛋白，发现其可通过竞争性结合PGE2阻断下游信号，显著抑制卵巢癌细胞的迁移和侵袭能力，提示其在癌症治疗中的潜在作用。
(注：以上文献信息为示例，实际引用需根据具体研究补充完整信息。)
**Background of EP2 Recombinant Protein**
The EP2 receptor, a G protein-coupled receptor (GPCR), is one of four subtypes (EP1-EP4) that mediate the biological effects of prostaglandin E2 (PGE2), a lipid signaling molecule involved in inflammation, immune regulation, and tissue homeostasis. EP2 activation primarily couples to Gαs proteins, triggering cAMP-dependent pathways that modulate cellular responses such as smooth muscle relaxation, vasodilation, and cytokine production. Its role in physiological and pathological processes, including pain perception, female reproductive functions, bone metabolism, and cancer progression, has made EP2 a target for therapeutic research.
Recombinant EP2 protein is engineered using heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional receptor proteins for *in vitro* studies. This technology allows researchers to study ligand-receptor interactions, signaling mechanisms, and receptor regulation without interference from endogenous cellular components. Epitope tags or fluorescent markers are often incorporated to facilitate detection, purification, or localization in assays.
In drug discovery, EP2 recombinant proteins are critical for high-throughput screening of agonists or antagonists, particularly in inflammatory diseases (e.g., arthritis), neurodegenerative disorders (e.g., Alzheimer’s, where neuroinflammation is implicated), and cancer (e.g., tumor microenvironment modulation). Recent studies also highlight its involvement in cyclic AMP-mediated pathways that influence immune cell behavior, making it relevant for immunotherapy research.
Despite its potential, challenges remain in achieving optimal receptor stability and post-translational modification fidelity in recombinant systems. Advances in structural biology (e.g., cryo-EM) and protein engineering continue to refine EP2 recombinant tools, enhancing their utility in both basic research and therapeutic development.
×
